Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery at Vienna Heart Center North Floridsdorf
January 11, 2021 at 04:03 pm IST
Share
Marizyme, Inc. announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company's product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients. . The hospital has a Heart and Vascular Center with a focus on aortic procedures and minimally invasive cardiovascular procedures and all techniques of CABG. The center performs approximately 500 CABG surgeries per year and is part of the ongoing DuraGraft EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits with DuraGraft to Evaluate the Safety and Performance of DuraGraft (VASC). Based on the performance of DuraGraft in improving patient outcomes, the Cardiac Surgery Center at Vienna Heart Center North Floridsdorf in August 2020 recognized DuraGraft as the standard-of-care for CABG surgeries.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery at Vienna Heart Center North Floridsdorf